Embecta's Q2: Revenue Drop, Strategic Shifts, and Growth Plans

Embectas Q2 performance disappoints with a 14.4% revenue drop, primarily due to US pen needle share losses and softer insulin pen volumes. The company slashes full-year 2026 revenue guidance and cuts dividend to one penny per share. However, theyre diversifying beyond diabetes injections, advancing GLP-one partnerships, and launching new products in India, Canada, and China. Despite financial pressures, they aim to repay $150 million in debt and review costs for growth in chronic care beyond insulin. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/4a920a15ef965778